Cybin Reports Second Quarter Financial Results and Recent Business HighlightsBusiness Wire • 11/15/23
Cybin Announces Closing of Offering of Units Led by One of the Company's Largest Institutional ShareholdersBusiness Wire • 11/14/23
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data AntNewsfile Corp • 11/01/23
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development PipelineBusiness Wire • 11/01/23
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023PRNewsWire • 10/31/23
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single DoseBusiness Wire • 10/31/23
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated ProgramsBusiness Wire • 10/26/23
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT ProgramBusiness Wire • 10/25/23
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic TherapeuticsBusiness Wire • 10/23/23
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development SummitBusiness Wire • 10/06/23
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive DisorderBusiness Wire • 10/03/23
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive DisorderBusiness Wire • 09/27/23
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 TrialBusiness Wire • 09/26/23
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive DisorderBusiness Wire • 09/21/23
Cybin shares continue to rise on major investment from Steve Cohen's hedge fundProactive Investors • 09/20/23
Cybin skyrockets as Steve Cohen's hedge fund Point72 purchases almost 19M sharesProactive Investors • 09/18/23